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r Res; 70(ermal growth factor receptor (EGFR) is a known diagnostic and, although controversial, prognostic
r of human glioblastoma multiforme (GBM). However, its functional role and biological significance
M remain elusive. Here, we show that multiple GBM cell subpopulations could be purified from the
ens of patients with GBM and from cancer stem cell (CSC) lines based on the expression of EGFR
f other putative CSC markers. All these subpopulations are molecularly and functionally distinct, are
igenic, and need to express EGFR to promote experimental tumorigenesis. Among them, EGFR-
sing tumor-initiating cells (TIC) display the most malignant functional and molecular phenotype.
ingly, modulation of EGFR expression by gain-of-function and loss-of-function strategies in GBM
nes enhances and reduces their tumorigenic ability, respectively, suggesting that EGFR plays a fun-
tal role in gliomagenesis. These findings open up the possibility of new therapeutically relevantdamen
scenarios, as the presence of functionally heterogeneous EGFRpos and EGFRneg TIC subpopulations within
the same tumor might affect clinical response to treatment. Cancer Res; 70(19); 7500–13. ©2010 AACR.tumor
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ells (CSC) in different types of tumors has raised many
tations. CSCs represent a rare fraction of the tumor
niquely responsible for tumor initiation and progres-
nd, as such, are envisioned as elective targets of ther-
1, 2). The CSC model of tumorigenesis has been
cingly validated in many hemopoietic malignancies
d in solid tumors such as breast and colon cancers, in other tumors, CSCs seem to make up
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-initiating cells (TIC; refs. 8–11).
s last model might also apply to glioblastoma multi-
(GBM), as soundly shown by recent studies in cultured
nes (12, 13). To test whether this concept might hold
specimens from patients with primary GBM, we se-
the epidermal growth factor receptor (EGFR) as a pro-
ve GBM CSC marker (14, 15). EGFR expression in GBM
th diagnostic and prognostic significance (16–19) and
ssociated with tumor progression (20). Likewise, EGFR
mplification is positively correlated with molecularly
d GBM subclasses, characterized by active proliferation
or prognosis (21). Valuable preclinical information has
een obtained by modulating EGFR expression in stan-
erum-cultured glioma cell lines (22–25) and by using
in vitro cultures for testing different therapeutic
aches (26).
e, we investigated the biological significance of EGFR
sion in human primary GBM by assessing its functional
n tumor cell fractions purified from several GBM
t–derived specimens and by validating it in GBM CSC
which reproduce the genotypic and phenotypic charac-
cs of GBM more faithfully than standard glioma cell
27, 28). By this experimental strategy, we identified mul-
ubpopulations of GBM TICs, each characterized by a
t gene signature and tumorigenic potential, and thus
able to reproduce the diverse pathologic and functional
es of GBM, such as invasive and angiogenic behavior.
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rials and Methods
tion and processing of patients' specimens
specimens were collected from patients with histo-
iagnosis of primary GBM (WHO grade 4 glioma) in ac-
nce with the protocol approved by the institutional
board of San Raffaele Scientific Institute (01-CSC07).
r diagnosis and grading were blind-reviewed by differ-
thologists at two distinct institutions. Samples that did
tisfy the inclusion criteria of primary GBMs (e.g., GBM
ligodendroglioma features) were excluded from the
. See Supplementary Experimental Procedure for
sing methods.
nohistochemical staining
r-micrometer sections were cut from paraffin blocks
ere stained with mouse antihuman EGFR, mouse
D31 (all DakoCytomation), rabbit anti-SOX2 (Abcam),
anti-Bmi1, and mouse anti-CD15 (Becton Dickinson).
ns were then incubated with a secondary antibody
MATE Envision Rabbit/Mouse, DakoCytomation).
ular analysis
al RNA from GBM tumor specimens and from CSC
as extracted using the RNeasy Micro and Mini Kits
n). cDNA was obtained by using Superscript RNaseH−
e transcriptase (Invitrogen). All cDNAs were normal-
the β-actin reverse transcription-PCR (RT-PCR) product.
ard RT-PCR for EGFRvIII was done as described in
.
escence-activated cell sorting
owing enzymatic and mechanical dissociation, cells
rimary GBM tissues and from experimental xenografts
stained with rabbit antihuman EGFR (clone EGFR.1,
erotec), rat antihuman CD34/CD45/CD11b (Becton
son), antihuman AC133 (Miltenyi), mouse anti-CD15
MMA, Becton Dickinson), and antihuman pan-HLA
n Dickinson). Cells were sorted on a Becton Dickinson
antage SE FACSDiVa. The purity of each cell fraction
between 90% and 99%. Fluorescence-activated cell
g (FACS) analysis of CSC lines was done as described
, without enzymatic digestion.
re propagation, population analysis,
loning
ablished GBM CSCs were cultured as previously
bed (27).array-based gene expression profiling
Supplementary Experimental Procedure for details.
the lo
(Dade
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ntation
origenicity was determined by injecting all the dis-
cell preparations orthotopically in nu/nu mice (27).
tic resonance imaging (MRI) analysis was performed
cribed in Supplementary Experimental Procedure.
unofluorescence analysis was performed on cryostat
ns using mouse monoclonal antihuman EGFR (1:100;
chem). Details can be found in Supplementary Data.
rn blotting
ates from GBM tissues and CSCs were immunoblotted
ing to standard protocols. The primary antibodies used
rabbit anti-EGFR, rabbit anti–phosphorylated EGFR
68; Cell Signaling), rabbit anti-ErbB2 (Calbiochem) and
anti-Erbb3 (Santa Cruz Biotechnology), rabbit anti–
horylatedmitogen-activated protein kinase (MAPK; Cell
ing), and rabbit anti–phosphorylated Akt (Ser473; Cell Sig-
). As a loading control, a mouse anti–β-tubulin antibody
sed (Sigma-Aldrich).
iral vector generation, production, and
fection
an wild-type (wt) EGFR cDNA (Upstate) was cloned
he monocistronic transfer lentiviral vector pCCL.sin.
PGK.GFP.WPRE11. CSCs were transduced with 1 × 107
uction units/mL of lentiviral vectors for 16 hours.
tiviral vectors coding for shRNAs targeted against the
n EGFR were purchased from Sigma (Mission RNAi).
ion of CSCs was performed according to the manufac-
instructions.
nofluorescence and fluorescence in situ
dization
unofluorescence was performed as described in
, using mouse antihuman EGFR (Calbiochem) and rab-
lyclonal anti-GFP (Molecular Probes). Fluorescence
hybridization (FISH) was performed using the kit from
according to the manufacturer's instructions. Filamen-
ctin (F-actin) was stained by TRITC-conjugated phal-
(Chemicon).
acologic EGFR inhibition in CSCs
478 (Calbiochem) was used at the indicated final con-
tions in complete medium. DMSO was used at the
concentration as the vehicle control. Cell proliferation
easured by an MTT incorporation assay.
ion assays
sion assays were performed in Matrigel-coated 8-μm-
Transwell chambers (Corning Costar). EGFRpos and
neg CSCs were seeded in sister cultures on the upper
f the chambers in complete medium and allowed to
te for 5 and 7 days, respectively, with or without
8. Noninvaded cells on the upper side of the filters
or were not scraped off, and those that migrated to
wer side were fixed and stained by using DiffQuick
Behring). The extent of cell migration was normalized
Cancer Res; 70(19) October 1, 2010 7501
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lts
expression identifies distinct cell subpopulations
human primary GBM and GBM CSC lines
eral GBM surgical specimens were tested for EGFR
expression by both microarrays and semiquantitative
R and all were shown to express the transcript (Table 1).
er, immunohistochemistry on corresponding paraffin-
ded sections showed that, in agreement with the liter-
only 50% of specimens were characterized by diffuse
staining, which was particularly intense in small-sized
tumor cells (EGFRpos tumor samples; Fig. 1A, Supple-
ry Fig. S1). Accordingly, the other specimens displayed
ible EGFR expression that was restricted mostly to
-infiltrating inflammatory cells (EGFRneg tumor sam-
ig. 1A). Western blotting (WB) analysis confirmed
munohistochemistry findings (Fig. 1B). Hence, EGFR
n distribution identifies two main distinct subtypes
an GBM (16).
FISH, a subset of EGFRpos tumor specimens showed
gene amplification and expression of mutant EGFRvIII
n some patients, correlated with EGFR protein levels
C and D; Table 1). Interestingly, EGFRpos tumors
ined small and thin CD31-positive vessels (Fig. 1E),
as EGFRneg tumors were characterized by an actively
rating vasculature [mean vessel area (±SEM), 853.1 ±
nd 2,500.2 ± 615.1 μm2 in EGFRpos and EGFRneg GBMs,
tively; P > 0.05, Student's t test; n = 7; Fig. 1E]. All spec-
expressed similar levels of stem cell–associated
ns, such as Sox2 and BMI1 (Fig. 1F), and of glial fibril-
idic protein (GFAP; data not shown).
restingly, whereas immunohistochemistry indicated
GFR was expressed in the totality of GBM cells, flow
etry suggested that EGFR expression could be re-
only in a smaller proportion of cells. Of note, with-
EGFRpos cell fraction, a conspicuous subset of cells
led with the endothelial marker CD34 and the hema-
tic markers CD45 and CD11b (Fig. 1G), indicating
hey were stromal cells. The CSC marker CD133
as more expressed in proper tumor cells than in
al cells in EGFRpos tumors, whereas the opposite
etected in EGFRneg tumors. On the contrary, CD15
lways more expressed in the stromal cell compart-
in both EGFRpos and EGFRneg tumors (refs. 31, 32;
mentary Table S1).
s, the frequency of EGFRpos proper tumor cells in
calculated after the exclusion of stromal cells, ranged
% to 35% of the total tumor cell number (Table 1). Of
some EGFRpos proper tumor cells also labeled with
and/or CD15 markers, whereas EGFRneg cells did
ig. 1F and H; Supplementary Table S2).
formally show that EGFR might also play a role in the
y of GBM CSCs in vitro, we tested 13 GBM CSC lines
usly validated for being bona fide CSC lines (Supple-
ry Fig. S2). All CSC lines expressed EGFR mRNA,
genes
fractio
r Res; 70(19) October 1, 2010
American Association Copyright © 2010 
cancerres.aacrjournalDownloaded from as only 5 of 13 CSC lines also expressed the EGFR pro-
able 2). Among the EGFRpos CSC lines, only 6% to 70%
s expressed the receptor, suggesting that multiple GBM
pulations could also be identified based on EGFR ex-
on in CSC lines.
restingly, many EGFRpos and EGFRneg CSC lines
ned AC133pos and CD15pos cells (Table 2; Supplemen-
able S3). However, one of five EGFRpos CSC lines and
f eight EGFRneg CSC lines did not contain any AC133pos
D15pos cells at all.
expression identifies GBM subpopulations with a
ctive gene signature
molecularly analyze the above-described GBM subpo-
ons, we purified them from (a) EGFRpos single patients'
specimens, (b) EGFRneg specimens, and (c) EGFRpos
nes.
Rpos patient samples T1224, T0131, T0222, and T0321
ned (a) EGFRpos/AC133neg cells (region R1), (b) EGFRpos/
pos cells (R2), and (c) EGFRneg/AC133neg (R3) cells. Two
also contained a small proportion of EGFRpos/CD15pos
Fig. 2A and B; Supplementary Table S2). Stromal cells
xcluded from sorting.
ediately after cell sorting and purity assessment,
ut any in vitro manipulation, the different GBM
ns were subjected to transcriptional profiling by
-transcript microarrays (Fig. 2C). EGFRpos cell subpo-
ons displayed a specific molecular signature clearly
uishable from that of double-negative cells (R3). Of
a subset of 163 genes was differentially expressed
en EGFRpos and EGFRneg cell subpopulations, even
isolated from distinct patient specimens, suggesting
GFR expression in GBM might affect common mo-
r determinants (Supplementary List S1). In addition
FR, the differentially expressed genes (DEG) upregu-
in EGFRpos versus EGFRneg GBM fractions were relat-
biological processes such as tumor invasion and
ession [e.g., periostin (POSTN), LMO3, and AQP4].
rsely, genes overexpressed in EGFRneg GBM fractions
ostly involved in the interaction of tumor cells with
icroenvironment [e.g., PDGFRB, Notch3, PTPRK, lumi-
LUM), and endothelin receptor A (EDNRA)]. Thus,
contain molecularly distinct subpopulations of
cells.
en the same freshly isolated cell fractions were cul-
in vitro by the NeuroSphere Assay under limiting di-
conditions (33), EGFRpos cell fractions gave rise to a
frequency of secondary neurospheres than EGFRneg
Fig. 2D).
l subpopulations expressing different levels of EGFR
lso purified from EGFRpos CSC lines (Fig. 2E–G). Im-
tely after sorting, EGFRhigh (R4), EGFRlow (R5), and
neg (R6) CSC subpopulations were validated by WB
H) and subjected to transcriptional profiling, which in-
d that each subpopulation was molecularly distinct
the others (Fig. 2I; Supplementary List S2). Of note,
upregulated in EGFRhigh and EGFRlow versus EGFRneg
ns were also highly expressed in the most malignant
Cancer Research
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Table R s n s
Patient
code
WHO Age/sex EGFR wt EGFR vIII EGFR gene EGFR protein EGFR protein
EGFRp
T01 M + a
T02 /F + + a
T12 M + a
T12 M + + a
T04
T06
T03 M + + a
EGFRn
T01 M + m
T01 M + m
T01 M + m
T01 /F + m
T03 M + m
T0512 IV 75/F 1+ 0 No amplification 5–10 1+
T1003 IV 65/M 1+ 0 No amplification 5–10 1+
Patient code Total EGFRpos cells (%) EGFRpos tumor cells (%) EGFRpos stromal cells (%)
EGFRpositive GBMs
T0131 20.8 4.0 16.8
T0222 76.8 35.2 41.6
T1210 13.7 10.7 3.0
T1224 78.1 20.3 57.8
T0418 36.6 12.4 24.2
T0625 22.4 8.9 13.5
T0321 39.1 21.7 17.4
EGFRnegative GBMs
T0104 4.9 0.9 4.0
T0109 17.3 0.0 17.3
T0125 19.0 1.6 17.4
T0130 25.3 3.3 22.0
T0325 0.0 0.0 0.0
T0512 4.4 0.0 4.4
T1003 7.5 0.0 7.5
NOTE: FISH scores: high gene amplification, >10 gene copies in >10% of the cells; low gene amplification, 6 to 10 gene copies in
>10% of the cells; high polysomy, >4 gene copies in >40% of the cells; low polysomy, >4 gene copies in >10% but <40% of the
cells; no amplification, 1 to 4 gene copies. Immunohistochemistry scores: 3+, very intense membrane staining; 2+, intense
membrane staining; 1+, moderate staining; 0, no staining.
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Published OnlineFirst September 21, 2010; DOI:10.1158/0008-5472.CAN-10-2353ular subclasses of primary GBM (i.e., the proliferative
esenchymal subtypes, as identified in refs. 21 and 34;
ementary Fig. S3). Likewise, genes downregulated in
os fractions were also downregulated in the same ma-
t molecular subtypes.
hown by clonogenic assays performed under limiting
n conditions and by long-term population analysis,low and EGFRneg cell fractions displayed the highest
rative capacity, whereas EGFRhigh cell subpopulations
EGFRn
Howe
acrjournals.org
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cancerres.aacrjournalDownloaded from d a transiently reduced growth ability that required a
bculturing passages to be completely restored to the
ting levels (Fig. 2J). All subpopulations contained the
percentage of Bmi1- and Sox2-expressing cells, which
t affected by cell differentiation (Supplementary Fig. S4).
en tested immediately after sorting, EGFRhigh and
ow fractions contained 100% of EGFRpos cells, whereas1. EGF expre sion in GBM patie ts' tumor pecimenseg fractions
ver, after s
 for Canc
 on Js.orgwere devoid of any EG
everal subculturing p
Cancer Res; 70
 er Research
une 12, 2012tumor
stage
mRNA mRNA amplification expression
(% of positive cells)
expression (membrane
staining intensity)os GBMs
31 IV 58/ 2 0 High mplification 70–90 3+
22 IV 57 2 1 High mplification 80–100 3+
10 IV 56/ 2 0 High mplification 80–100 3+
24 IV 59/ 2 1 High mplification 70–90 3+
18 IV 63/ 1 0 High olysomy 70–90 2+M + p
25 IV 74/F 1+ 0 Low amplification 70–90 2+
21 IV 59/ 2 1 High mplification 70–90 3+
eg GBMs
04 IV 49/ 1 0 No a plification 10–20 1+
09 IV 47/ 1 0 No a plification 10–20 1+
25 IV 49/ 1 0 No a plification 10–20 1+
30 IV 72 1 0 No a plification 15–25 1+
25 IV 51/ 1 0 No a plification 0 0FRpos cells (Fig. 2K).
assages, each cell
(19) October 1, 2010 7503
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Published OnlineFirst September 21, 2010; DOI:10.1158/0008-5472.CAN-10-23531. EGFR expression identifies distinct cell subpopulations within primary human GBM. A, EGFRpos GBM tumors show diffuse and intense reactivity
R in small and round neoplastic cells (T1224). EGFRneg GBM specimens show EGFR staining restricted to tumor-infiltrating inflammatory cells
rrow; T0109). Magnification, ×400 and ×800. B, WB confirms EGFR protein levels in GBM patients' specimens. C, FISH analysis indicates
EGFR gene is amplified only in EGFRpos tumors. D, the mutant EGFRvIII can be detected in a subset of EGFRpos tumors by RT-PCR. E, EGFRpos
contain modestly proliferating vessels (arrows), whereas EGFRneg tumors show an enlarged and proliferating vasculature (arrows). H&E and
taining; magnification, ×200 and ×400. F, EGFRpos and EGFRneg tumors contain similar numbers of Sox2 and Bmi1pos cells. CD15pos proper tumor
n be detected only in EGFRpos (arrow at bottom right, CD15pos monocytes within a vessel). Magnification, ×400. G, in EGFRpos tumors, many
s cells are proper tumor cells, whereas in EGFRneg tumors the few EGFRpos cells are stromal/inflammatory cells. H, the EGFRpos fractions from
s pos pos negspecimens contain AC133 and CD15 cells (top middle), which are either tumor cells or stromal cells. On the contrary, EGFR fractions
ht) and EGFRneg GBM tumors (bottom) contain only stromal AC133pos and CD15pos cells.
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eg cells found in the parental bulk population, recapit-
g the original cellular heterogeneity (Fig. 2K).
expression confers increased tumorigenic
ity to GBM cells
assess whether EGFR expression might affect the tu-
enic ability of GBM cells, R1, R2, and R3 fractions,
d from EGFRpos GBM specimens, were transplanted
e brain of nu/nu mice, without any prior in vitro ma-
tion (Fig. 3A; Supplementary Fig. S1). MRI-based
etric analysis showed that EGFRpos cells were charac-
by enhanced tumorigenic capacity (Fig. 3A). How-
GFRneg/AC133neg cells were also capable of initiating
s, although these developed significantly more slowly
hose generated by EGFRpos GBM cells (Kaplan-Meier
is; Fig. 3B).
ably, EGFR expression was retrieved not only in xeno-
derived from EGFRpos cells but also in those derived
EGFRneg fractions (Fig. 3C–E). Importantly, the latter
rafts never contained either AC133pos cells (Fig. 3E)
15pos cells (Fig. 3F, Supplementary Fig. S1). Thus, as re-
shown for other stem cell markers in melanoma (35),
expression in GBM TICs is dynamically regulated,
that EGFRneg cells can become EGFRpos on transplan-
. Most importantly, EGFR expression positively corre-
ith gliomagenesis.
xenog
from
acrjournals.org
American Association Copyright © 2010 
cancerres.aacrjournalDownloaded from ough R1-, R2-, and R3-derived xenografts showed the
expression of SOX2 and Bmi1 (Fig. 3G and data not
), they were molecularly different (Fig. 3H). By micro-
based analysis, proinvasive genes were overexpressed
FRpos cell–derived xenografts, whereas genes involved
iogenesis were upregulated in EGFRneg cell–derived
rafts (Supplementary Fig. S5).
greement with these latter findings and with molec-
ata obtained on EGFRpos and EGFRneg subpopulations
C), xenografts from EGFRpos cells were shown to be
invasive, with cells spreading preferentially along the
atter while avoiding white matter fiber tracts (Fig. 3C
; Supplementary Figs. S1 and S6). On the contrary,
s formed by EGFRneg cells showed well-demarcated
aries, with cells migrating preferentially along white
r tracts (Fig. 3C and G; Supplementary Figs. S1 and
ccordingly, EGFRpos cell–induced xenografts were
terized by thin, regularly shaped blood vessels and
proliferative index, whereas tumors from EGFRneg
contained enlarged and proliferating vessels and a
frequency of mitotic cells (Supplementary Figs. S1
6).
s, EGFR expression confers different invasive, angio-
and tumorigenic abilities to GBM cells in vivo.
ably, the same functional differences observed between2. Character
enrichment mation of
rkers ACGFRpos a
33 and Cd EGFRneg GBM C
15r
G
sC lines for theirafts generated by EG
BM specimens coul
C
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(19) October 1iveine code EGFR wt
mRNA
EGFR vIII
mRNA
EGFR gene
amplification (FISH)
PTEN expression
(WB)
EGFRpos
cells (%)
AC133pos
cells (%)
CD15pos
cells (%)ositive CSC lines
27 2 High mplification 2+ 25.8 3.5 42.9 15.2 22.3 2.9
04 2 High olysomy 0 7.7 1.2 5.9 0.9 2.7 1.0
06 2 Low mplification 3+ 21.1 3.0 0 28.1 2.9+ 0 a ± 0. ±
01 2+ 0 High polysomy 1+ 79.1 ± 3.9 3.1 ± 1.5 13.7 ± 0.9
05 2 Low olysomy 0 8.5 2.8 0 0
egative CSC lines
04 1 No a plification 0 2.0 0.8 30.1 13.8 50.8 3.2
23 1 No a plification 3+ 0 0 10.7 1.3
25 1 No a plification 1+ 0 0 0
10 1 No a plification 0 2.4 1.2 0 0
14 1 No a plification 3+ 0 0 5.9 1.7
25 1 No a plification 0 0 0 003 + 0 m .0 0. .0
0512 1+ 0 No amplification 3+ 1.7 ± 0.6 2.1 ± 1.4 11.7 ± 2.9
0418 1+ 0 No amplification 0 0.0 18.2 ± 4.5 0.0
E: EGFR wt and EGFRvIII mRNA levels were measured by semiquantitative RT-PCR. EGFR, AC133, and CD15 expression was
sured by flow cytometry. High gene amplification, >10 gene copies in >10% of the cells; low gene amplification, 6 to 10 gene
ies in >10% of the cells; high polysomy, >4 gene copies in >40% of the cells; low polysomy, >4 gene copies in >10% but <40%
he cells; no amplification, 1 to 4 gene copies. The frequency of EGFRpos cells within EGFRpos CSC lines remained stable
ughout extensive subculturing. Likewise, EGFRneg CSC lines were never shown to comprise EGFRpos cells even at very highurified
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FRpos/AC133pos (R2), and EGFRneg/AC133neg (R3) cells were isolated from EGFRpos tumor specimens by FACS (IgGs, isotype controls). C, global gene
iondata in R1, R2, and R3 fractions purified from patients' specimens (left). The expression of a selection of coregulated genes is highlighted in the heatmaps
, limiting dilution clonogenic assay of R1, R2, and R3 fractions immediately after sorting. E, different CSC lines comprise variable amounts of EGFRpos
agnification, ×200 (insets, ×600). F, some EGFRpos CSCs display EGFR gene amplification. G, different CSC subpopulations could be isolated by FACS
FRpos CSC lines based on their EGFR expression (region R4, EGFRhigh CSCs; R5, EGFRlow CSCs; R6, EGFRneg CSCs; L0627). H, WB analysis shows that
activated in EGFRhigh and EGFRlow CSCs but is absent in EGFRneg CSCs. I, global gene expression data of R4, R5, and R6 GBM fractions purified from
sCSC lines.SemiquantitativeRT-PCRvalidationofDEGs. J, clonogenic assayand long-termgrowthcurvesofR4,R5, andR6CSCs immediately after sorting
r in vitro culture. K, EGFR expression in CSC fractions immediately after sorting (top) and on in vitro culture (bottom; EGFR, green; magnification, ×200).
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Published OnlineFirst September 21, 2010; DOI:10.1158/0008-5472.CAN-10-23533. EGFR expression identifies TICs with different tumorigenic capacities. A, EGFRpos cell–derived tumors, independently of the coexpression of
were significantly larger than tumors induced from EGFRnegAC133neg cells. P < 0.05, one-way ANOVA with Bonferroni test (n = 5, six independent
ents). B, Kaplan-Meier survival curves (P < 0.01). C, EGFR expression detected by an antihuman EGFR is retrieved in all xenografts, including
gAC133neg cell–derived tumors (EGFR, green). EGFRpos cell–derived tumors are characterized by an infiltrative pattern of growth. Tumor cells
e within the gray matter, avoiding the corpus callosum (white arrow). EGFRnegAC133neg cells give rise to expanding tumors, mostly confined within
ction site, which migrate and invade along white matter tracts (white arrowhead). D, WB confirms EGFR protein expression in all xenografts.
ame distinct EGFRpos and EGFRneg subpopulations as detected in the parental tumor were retrieved in the corresponding xenografts by flow
try. CD15pos cells (F) were not retrieved in any xenografts by immunohistochemistry. G, a similar frequency of Sox2 and Bmi1 immunoreactive cells
e retrieved in R1- and R3-derived xenografts. H, global gene expression data of R1- and R3-derived xenografts. I to J, EGFR expression
enhanced tumorigenic potential to EGFRpos fractions from EGFRpos CSC lines (one-way ANOVA with Bonferroni test, n = 5, three independent
ents). P < 0.01, Kaplan-Meier survival curves. K, EGFR expression was retrieved in all xenografts, whereas ErbB2 was highly expressed
EGFRhigh CSC–derived tumors (WB).
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Published OnlineFirst September 21, 2010; DOI:10.1158/0008-5472.CAN-10-2353ted by in vitro expanded EGFRpos and EGFRneg CSC
Supplementary Fig. S2; ref. 36).
ause EGFR expression in EGFRneg cell–derived xeno-
might be due to contaminating EGFRpos tumor cells,
rified EGFRneg tumor cells from EGFRneg specimens
ere totally devoid of EGFRpos, AC133pos, and CD15pos
r tumor cells (Fig. 1A, G, and H; Supplementary
S1). FACS-purified EGFRneg/AC133neg cells generated
rafts that expressed EGFR but were negative for
and CD15, thus confirming that EGFR might indeed
prominent role in glioma formation (Supplementary
). Notably, both in vivo limiting dilution analysis and
transplantation proved that all GBM subpopulations
ied based on EGFR expression could be considered
fide TICs (Supplementary Fig. S8).
tumorigenic potential of EGFRhigh, EGFRlow, and
eg cells purified from different EGFRpos CSC lines
2G and 3I and J and Supplementary Fig. S9 for
and Supplementary Fig. S9 for L0605) was also
. As observed for xenografts obtained from GBM
en–derived subpopulations (Fig. 3A–E), tumors de-
from EGFRhigh and EGFRlow CSCs were larger than
generated from EGFRneg cell fractions, which, again,
yed tumor-initiating ability (Fig. 3I and J). Again,
neg CSC fraction–derived tumors expressed EGFR,
ming that EGFR upregulation occurred during ex-
ental tumorigenesis (Fig. 3K). ErbB2 expression
etected only in EGFRhigh cell–derived tumors, sug-
g that the xenografts were molecularly heterogeneous
K).
understand the relationship between the expression of
and that of the CSC markers CD15 and AC133 in
of tumor-initiating potential, EGFRposCD15neg (R4),
posCD15pos (R5), EGFRnegCD15pos (R6), and EGFRneg
eg (R7) as well as EGFRposCD15negAC133neg (R1) and
egCD15negAC133neg (R3) fractions were purified from
and L0605 (Supplementary Fig. S9). Interestingly,
os subpopulations, independent of the coexpression
133 and/or CD15, generated tumors that developed
earlier and grew larger than those generated by
eg fractions. Consistent with previous findings, CSC
ubpopulations negative for EGFR, AC133, and CD15
ated xenografts that did not express either of the
arkers in vivo but did express the EGFR (Supplemen-
igs. S2 and S9).
s, all of our GBM CSC lines, taken as a whole or frac-
ed into subpopulations and independent of their basal
expression, gave rise to xenografts that upregulated
GFR significantly (Fig. 3K; Supplementary Figs. S2
9). To understand the mechanism underlying EGFR
sion in EGFRneg cell–derived xenografts, we hypothe-
that because EGFRneg GBM cells retain EGFR tran-
expression (Tables 1 and 2; Fig. 2C and I), in vivo
expression might be regulated posttranscriptionally.
, when we simulated in vitro the mitogen-reduced
brain microenvironment by starvation, EGFRneg CSCs
ntly reexpressed the EGFR protein (Supplementary
). Accordingly, when the same CSCs were reexposed
increa
mice
r Res; 70(19) October 1, 2010
American Association Copyright © 2010 
cancerres.aacrjournalDownloaded from ndard mitogen concentrations, they downregulated
expression, as may occur in vivo during tumor pro-
n when tumor-infiltrating stromal cells secrete mito-
n a paracrine fashion (37).
ced EGFR expression by gene transfer increases
alignant behavior of CSCs in vitro and in vivo
tiviral vector–mediated EGFR expression in three
t EGFRneg CSC lines allowed the expression of a ful-
ctional receptor (Fig. 4A). Of note, the majority of
transduced cells acquired a fibroblastoid shape and
ped stress fibers and actin-driven lamellipodia, all
markers of epithelial-mesenchymal transition and
ced malignancy (Fig. 4B; Supplementary Table S4).
tently, the average cell size was increased in most
transduced cells (Fig. 4C; Supplementary Table S4).
e expression profiling of naïve, mock, and EGFR-
pressing CSC lines identified a common subset of
that was altered in both L0104 and L0125 CSC lines,
sting that enforced EGFR expression affected the
molecular determinants in different patient-derived
ines (Fig. 4D and E). In addition to EGFR, LIF, and
, genes previously shown to be also highly expressed
CS-purified EGFRpos CSC fractions (Fig. 2I; Supple-
ry List S2), proinvasive genes such as CXCL10 and
(38, 39) were upregulated in EGFR-transduced CSCs
D–E) and also overexpressed in the proliferative and
chymal subtypes of human GBM (ref. 2I; Supplemen-
ig. S3). Accordingly, tumor suppressors such as
L1 (Fig. 2I), ERBB4, ASCL1, and EDNRB, which were
egulated in EGFR-transduced CSCs, were also down-
ted in GBM malignant subtypes.
ably, all EGFR-transduced CSC lines formed experi-
l tumors that were larger than those induced by the
ponding mock lines (Fig. 4F).
ic loss of function of EGFR reduces the
nancy of CSCs in vitro and in vivo
silence EGFR expression stably, we exploited line
and line L0627, which express high levels of EGFR
and 30% of the cells, respectively (Table 2). The
clones 204 and 206 induced EGFR protein knock-
with an efficiency of 60% and 70% in lines L0201
A) and L0627 (data not shown), respectively. WB anal-
nfirmed the flow cytometry results and indicated an
tion of downstream signaling pathways on EGFR
ing (Fig. 5B).
R-knockdown CSCs displayed morphologic changes
o, with neurospheres appearing as well-differentiated
Fig. 5C). Consistently, the frequency of differentiated
etected in shRNA-transduced CSCs increased under
roliferative (Fig. 5D) and differentiative culture condi-
(data not shown).
note, tumors generated from EGFR-knockdown CSCs
ped more slowly and were significantly smaller than
generated by the CTRL subclone, thus resulting in the
sed survival of EGFR-knockdown CSC–transplanted
(Fig. 5E).
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Published OnlineFirst September 21, 2010; DOI:10.1158/0008-5472.CAN-10-23534. Overexpression of EGFR enhances the tumorigenic potential of CSCs. A, lentiviral-mediated EGFR gene transfer resulted in the expression of
ional EGFR, as indicated by phosphorylation at residue Tyr1068 and by the hyperactivation of downstream pathways. B, enforced EGFR expression
neg CSCs (EGFR, red) correlates with changes in cell morphology, which are absent in GFP-transduced CSCs (GFP, green). F-actin staining
din, red). Magnifications: top, ×400; insets, ×1,000; bottom, ×1,000. C, EGFR overexpression in EGFRneg CSCs induces a significant increase in their
C-A and SSC-A. D, global gene expression data in naïve, mock-transduced, and EGFR-transduced CSC lines identify a subset of DEGs that
egulated in different patient-derived CSC lines and modulated by enforced EGFR expression (EGFR gene signature). E, semiquantitative RT-PCR
negon of DEGs. F, ectopic expression of EGFR in EGFR CSC lines increases their tumorigenic potential and reduces mouse survival (Student's
= 5, three independent experiments).
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Published OnlineFirst September 21, 2010; DOI:10.1158/0008-5472.CAN-10-23535. Inhibition of EGFR expression and activity negatively affects the malignant behavior of CSCs. A and B, flow cytometry and WB of L0201
204 and shRNA 206 CSC subclones indicate efficient knockdown of EGFR protein and downregulation of MAPK and Akt downstream pathways.
, EGFR knockdown induces CSC differentiation. Tuj1, red; GFAP, green. Magnifications: top, ×200; bottom, ×400. *, P > 0.05, Student's t test.
R silencing in CSCs significantly decreases their tumorigenicity (one-way ANOVA with Bonferroni test, n = 4, two independent experiments).
1, Kaplan-Meier survival curves. F, AG1478 treatment inhibits the phosphorylation status of EGFR and Akt in CSCs (WB). G, EGFRpos CSC lines
d to treatment by decreasing their proliferation/survival, whereas EGFRneg CSC do not. *, P > 0.05; **, P > 0.01, Student's t test. H and I, EGFR
n by AG1478 negatively affects the invasive ability of CSCs. **, P > 0.01, Student's t test. J, CSC responsiveness to TKI is independent of
xpression (WB).
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so to the existence of genetically and functionally dis-
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ine with recent reports that provide new interpreta-
of the process of tumorigenesis in mouse hemato-
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at the initiation and progression of GBM may not de-
n the presence of a single and rare fraction of CSCs, as
sed by the hierarchical model of tumor development
n the contrary, our data propose a different biological
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nt degrees of stemness as proven by their different tu-
enic ability and by their distinct phenotypic and molec-
eatures (44). In fact, all of our GBM-derived TIC
pulations satisfy the requirements for bona fide CSCs:
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ial transplantation.
ed on these observations, GBM tissue heterogeneity
be explained by the presence of a hierarchy of distinct
as recently suggested for in vitro generated GBM CSC
13). These distinct TICs distribute along a gradient of
GBMs
on rec
acrjournals.org
American Association Copyright © 2010 
cancerres.aacrjournalDownloaded from igenic potential that is strictly associated with EGFR
sion.
s, our study provides conclusive evidence that the ma-
of GBM cells have tumorigenic capacity and that the
chical model of tumorigenesis might not fully apply
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anisms underlying EGFR-dependent
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or cells might modify their phenotype during tumor
ssion, with multiple cohorts of TICs being generated
n this study, we have shown that EGFR expression
butes to GBM cell diversity by generating different
opulations. As to the mechanisms involved in the
ation of EGFR-dependent phenotypic heterogeneity
M, the contribution of tumor microenvironment
to be taken into consideration. Paracrine EGFR li-
, such as epidermal growth factor, are released by
stromal cells that, in this way, contribute to the ac-
n of the EGFR signaling in both proper tumor cells
ndothelial cells (37). When stroma-produced epider-
rowth factor is secreted, EGFR protein downregula-
ccurs in target cells by receptor internalization,
ed by lysosomal degradation.
line with this view, it is tempting to speculate that
GFRneg cell component detected in EGFRpos GBM
be generated from GBM cells that were originally
pos through receptor downregulation induced by ex-
e ligand stimulation during tumor progression, as
ulated in vitro by modulation of mitogen concentra-
n addition, termination of EGFR signaling in EGFRneg
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r differences detected between EGFRpos and EGFRneg
For instance, the expression of other receptor tyro-
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d tumorigenic potential and highly invasive behavior,
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egulation, being reactivated on exposure to appropri-
imuli when exposed to the in vivo microenvironment.
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